Alpha blockers help voiding in patients with MS

Overmyer, Mac
June 1998
Urology Times;Jun98, Vol. 26 Issue 6, p15
Provides information on the therapy devised by researchers from the Temple University School of Medicine in Philadelphia, Pennsylvania, for multiple sclerosis patients with voiding dysfunction. Basis of the research; Average bladder capacity of the participants of the experiment; Side effects of the therapy.


Related Articles

  • Pizzas stimulate vaginal infections.  // Nutrition Health Review: The Consumer's Medical Journal;1995, Issue 74, p6 

    Reports that researchers from the Temple University School of Medicine found that their is a connection between the consumption of pizzas and vaginal yeast infection. What is the connection.

  • Drug to treat spasticity available under treatment IND.  // FDA Consumer;Jun90, Vol. 24 Issue 5, p5 

    Reports that baclofen for infusion into the spinal canal is now available under the treatment IND (investigational new drug) Program for persons with multiple sclerosis or spinal cord injury suffering from severe and chronic spasticity who cannot tolerate or who do not respond to oral baclofen.

  • Magnets give new hope to multiple sclerosis victims.  // Second Opinion;Nov96, Vol. 6 Issue 11, p1 

    Reports on the use of magnetic therapy in the treatment of multiple sclerosis (MS). Placing of the magnets in the temples for 30 minutes; Stimulation of the pineal gland to produce serotonin and other neurotransmitters.

  • The strategies of coping with multiple sclerosis. Cichoke, Anthony J. // Total Health;Apr93, Vol. 15 Issue 2, p32 

    Provides advice for people afflicted with multiple sclerosis. Theories on causes of the disease; Destruction of myelin; Diet therapy; Vitamin Supplements.

  • Drug reduces MS relapse.  // Drug Topics;11/7/94, Vol. 138 Issue 21, p25 

    Reports that Copolymer 1 reduces the relapse rate in patients with exacerbating-remitting multiple sclerosis.

  • Investigational interferon-beta therapy shows clinical effectiveness in treating patients with...  // Formulary;Nov95, Vol. 30 Issue 11, p655 

    Reports that the recombinant interferon beta (IFN-beta-1A) has an impact on the clinical course of multiple sclerosis (MS). Exacerbation rate in patients using IFN-beta-1A; Percentage of MS patients that can be helped through interferon beta.

  • Long-term immunological changes in azathioprine-treated MS patients. Corsini, E.; La Mantia, L.; Gelati, M.; Dufour, A.; Milanese, C.; Massa, G.; Nespolo, A.; Salmaggi, A. // Neurological Sciences;Apr2000, Vol. 21 Issue 2, p87 

    The long-term immunological effects of azathioprine treatment have been investigated in 8 multiple sclerosis patients with different course of disease, chronic progressive (CP) or relapsing progressive (RP). We studied fluctuations in peripheral blood mononuclear cell subsets, IgG, IgM and...

  • Placebos. Foley, Frederick // Inside MS;Summer92, Vol. 10 Issue 2, p18 

    Evaluates the importance of placebos in the treatment of multiple sclerosis. Development of the definition; Aspects; History of placebos in medicine; Biological basis of the placebo effect; Conditioning; Placebo effects and origin in studies of MS treatments; Key questions raised. INSET: Some...

  • FDA approval for the baclofen pump for severe spasticity.  // Inside MS;Fall/Winter92, Vol. 10 Issue 3, p10 

    Announces the Federal Food and Drug Administration's approval of a preparation of baclofen delivered by an implanted computer-driven pump for use in treating severe intractable spasticity. Medication for multiple sclerosis; Intrathecal delivery action of baclofen; Inadequacy of oral doses of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics